Grifols

$18.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.17 (-0.90%) Today
$0.00 (0.00%) As of 4:00 PM EST after-hours

Why Robinhood?

You can buy or sell Grifols and other stocks, options, and ETFs commission-free!

About GRFS

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain. The listed name for GRFS is Grifols, S.A. American Depositary Shares.

CEO
Raimon Grifols Roura
Employees
24,016
Headquarters
Barcelona, Catalonia
Founded
1940
Market Cap
4.82B
Price-Earnings Ratio
16.60
Dividend Yield
1.61
Average Volume
904.55K
High Today
$18.98
Low Today
$18.45
Open Price
$18.76
Volume
477.46K
52 Week High
$25.73
52 Week Low
$13.40

Collections

GRFS Earnings

$0.00
$0.11
$0.21
$0.32
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
Expected Dec 4, Pre-Market

You May Also Like